Anti-Osteopenic Effect of Nasal Salmon Calcitonin in Type 1 Osteoporotic Rats: Comparison with Subcutaneous Dosing.

• 市川 正樹

• 中牟田 弘道

• 星野 崇

• 小川 保直

• 小井田 雅夫

抄録

The anti-osteopenic effect of nasal salmon calcitonin (SCT) was investigated in a type 1 osteoporotic model, Wistar rats which were ovariectomized (OVX) at age of 12 weeks, and compared with that of subcutaneous SCT. It was proved that nasal (5, 10, 20 and 40 U/rat) and subcutaneous (5, 10 and 20 U/kg) administration of SCT on alternate days for 3 weeks, starting a week after OVX, prevented the osteopenic changes of tibia and lumbar vertebra; this was proved by physicochemical parameters and histomorphometrically. A clear dose-dependent effect was seen in the trabecular bone volume of a selected regions of the 5th lumbar vertebra, and the ED₅₀s of nasal and subcutaneous SCT calculated were 7.4U/rat and 3.5U/kg, respectively. The results indicate that nasal SCT is absorbed effciently in rats with increased bone turnover to prevent rapidly developing osteopenia and that the administration route is a suitable standard method for chronically giving biodegradable anti-osteoporotic peptides to rats.

収録刊行物

• Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ

  Ｂｉｏｌｏｇｉｃａｌ　＆　Ｐｈａｒｍａｃｅｕｔｉｃａｌ　Ｂｕｌｌｅｔｉｎ 17 (7), 911-913, 1994

  公益社団法人 日本薬学会

キーワード

• calcitonin
• anti-osteopenic
• nasal
• osteoporosis
• histomorphometry
• bioavailability

詳細情報

• CRID: 1390282679598503296
• NII論文ID: 110003640674
• NII書誌ID: AA10885497
• DOI: 10.1248/bpb.17.911
• COI: 1:CAS:528:DyaK2MXivV2hs70%3D
• ISSN: 13475215
• ISSN: 09186158
• PubMed: 8000375
• Web Site: http://www.jstage.jst.go.jp/article/bpb1993/17/7/17_7_911/_pdf
• Web Site: https://search.jamas.or.jp/link/ui/1995095712
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • PubMed
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可